ArticleDiabetes technology & therapeutics2019
Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study.
Open access · greenAbstract read
In one paragraph
Article in Diabetes technology & therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 3 pooled it
11.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Disparities in GLP-1RA and SGLT2i Uptake: a Systematic Review and an Equity-First Framework for Cardiovascular-Kidney-Metabolic Care.Current cardiology reports · 2026Pooled it
- Evidence-Based Practice in Prescribing SGLT2i and GLP-1 RA Across Ethnic and Racial Groups: a Systematic Review and Meta-analysis of Observational Studies.Journal of racial and ethnic health disparities · 2026Pooled it
- Pooled it
- Trends in sodium-glucose transport protein 2 inhibitor prescriptions: application of the ATC/DDD system to NDB open data.Diabetology international · 2026Article
- Low uptake and disparities in therapeutic inertia of cardiorenal protective diabetes medications for patients with type 2 diabetes and above-target hemoglobin A1c.BMJ open diabetes research & care · 2026Article
- National trends in resmetirom prescriptions for metabolic dysfunction-associated steatohepatitis in the USA.Clinical and molecular hepatology · 2026Article
- Review
- Fill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012-2021.Journal of general internal medicine · 2026Article
- Knowledge, attitudes, and practices of Saudi physicians toward the use of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus: a nationwide cross-sectional study.Frontiers in endocrinology · 2026Article
- Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) Prescription Rates Amongst Diabetologists for Type 2 Diabetes Patients with Albuminuric Diabetic Kidney Disease: A Real-World Study at a Diabetes Center in Bangkok.Journal of the ASEAN Federation of Endocrine Societies · 2025Article
- SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular-Kidney-Metabolic Syndrome.Biomedicines · 2025Review
- Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk.Journal of the American Heart Association · 2025Article
- Heterogeneous effects of sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors on nephrolithiasis in older adults with type 2 diabetes.Pharmacotherapy · 2025Article
- Evaluating Guideline Alignment by Analyzing Patient Profiles of Elderly People with Type 2 Diabetes and Chronic Kidney Disease Treated or Not with SGLT2 Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Evaluating the appropriateness and the factors associated with sodium-glucose co-transporter 2 inhibitors prescribing in a Middle Eastern country: a cross-sectional study.International journal of clinical pharmacy · 2025Article
- Factors and Disparities Influencing Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists Initiation in the United States: A Scoping Review of Evidence.Pharmacy (Basel, Switzerland) · 2025Review
- Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes.Diabetes, obesity & metabolism · 2024Article
- Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study.Journal of general internal medicine · 2024Article
- Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease.Cardiovascular diabetology · 2024Observational
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Rozalina G McCoyDivision of Community Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Hayley J DykhoffDivision of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Lindsey SangaralinghamDivision of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Joseph S RossNational Clinician Scholars Program, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Pinar Karaca-MandicCarlson School of Management, University of Minnesota, Minneapolis, Minnesota.
Victor M MontoriDivision of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Nilay D ShahDivision of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.
Mayo Clinic · USMayo Clinic in Arizona · USOptum (United States) · USUniversity of Minnesota · USYale New Haven Hospital · US
Funding
Understanding and Improving Healthcare Decision-Making and Outcomes for People Living with Alzheimer's Disease and Related DementiasP01AG005842 · NIA · NATIONAL BUREAU OF ECONOMIC RESEARCH · PI Katherine Baicker · 1986 to 2026
$56.5MYale-Mayo FDA Center for Excellence in Regulatory Science and InnovationU01FD005938 · FDA · YALE UNIVERSITY · PI Joseph Solomon Ross · 2016 to 2026
$25.4MPA-20-072: Accelerating the Use of Evidence-based Innovation in Healthcare SystemsU19HS024075 · AHRQ · DARTMOUTH COLLEGE · PI MEARA, ELLEN R. · 2015 to 2021
$19.8MShared decision making for stroke prevention in atrial fibrillation (SDM4Afib)R01HL131535 · NHLBI · MAYO CLINIC ROCHESTER · PI MONTORI, VICTOR MANUEL · 2016 to 2020
$3.2MUnderstanding hospital value: provider, hospital and community effectsR01HS022882 · AHRQ · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HORWITZ, LEORA · 2014 to 2023
$2.9MGastrointestinal Safety of Antithrombotic Drug RegimensR01HS025402 · AHRQ · MAYO CLINIC ARIZONA · PI ABRAHAM, NEENA S · 2017 to 2020
$1.6MMedical reversals: De-implementing ineffective and unsafe treatmentsR01HS025164 · AHRQ · UNIVERSITY OF MINNESOTA · PI KARACA-MANDIC, PINAR · 2017 to 2020
$1.4MPredicting the Risk of Severe Hypoglycemic and Hyperglycemic Events in Adults with DiabetesK23DK114497 · NIDDK · MAYO CLINIC ROCHESTER · PI MCCOY, ROZALINA GRUBINA · 2017 to 2021
$846kDiffusion of Clinical Evidence into Practice: Physician Networks, Delivery Organizations, and MarketsR56HL130496 · NHLBI · UNIVERSITY OF MINNESOTA · PI KARACA-MANDIC, PINAR · 2016 to 2016
$634kOptimizing Medical Device Post-Market Surveillance for Public ValueU01FD004585 · FDA · YALE UNIVERSITY · PI KRUMHOLZ, HARLAN MARC · 2012 to 2016
$592kThe ICAN Discussion Aid to Optimize Treatment for People Living with Multiple Chronic ConditionsR03HS025517 · AHRQ · MAYO CLINIC ROCHESTER · PI SHAH, NILAY D · 2017 to 2018
$100kAHRQ HHS R01 HS022882AHRQ HHS R01 HS025164AHRQ HHS R01 HS025402AHRQ HHS R03 HS025517AHRQ HHS U19 HS024075FDA HHS U01 FD004585FDA HHS U01 FD005938NHLBI NIH HHS R01 HL131535NHLBI NIH HHS R56 HL130496NIA NIH HHS P01 AG005842NIDDK NIH HHS K23 DK114497
Abstract
PubMed holds no abstract for this paper.
Indexed as
Practice Patterns, Physicians'AdultAgedAge FactorsBenzhydryl CompoundsCanagliflozinCohort StudiesDiabetes Mellitus, Type 2Drug PrescriptionsFemaleGlucosidesHumansHypoglycemic AgentsMaleMedicareMiddle AgedBenzhydryl CompoundsCanagliflozindapagliflozinempagliflozinGlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsAdministrative claims dataDiabetes mellitusEvidence-based medicineHealth services researchPharmacoepidemiologySGLT2 inhibitor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.